Loading...

RHHBY - Roche Holding AG

Analyst Downgrade Signal for 01-16-2024
Analyst Downgrade Signal: RHHBY from Equal-Weight to Underweight by Morgan Stanley
Price Target: $--


Loading Chart RHHBY

Stock Signal Information


Signal

Analyst Downgrade Signal: RHHBY from Equal-Weight to Underweight by Morgan Stanley
Price Target: $--
Report Date: 01-16-2024
Symbol: RHHBY - Roche Holding AG
Sector: Healthcare
Industry: Drug Manufacturers—General
Analyst Downgrade Signal: RHHBY from Equal-Weight to Underweight by Morgan Stanley
Price Target: $--

  RHHBY Technical Analysis

Company Contact

Roche Holding AG (RHHBY)
Konzern Hauptsitz
Basel, 4070
Phone: 41 61 688 11 11
Website: https://www.roche.com
CEO:

RHHBY, Roche Holding AG

RHHBY Roche Holding AG Logo Image

OTC, Other OTC


Company Profile

Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, the company supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. It has collaboration with Gilead Sciences, Inc. for COVID-19; and a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza. The company also has a collaboration with Bristol Myers Squibb to advance personalized healthcare through digital pathology solutions. The company was founded in 1896 and is headquartered in Basel, Switzerland.